INNOVADERM CRO IS NOW INDERO.

Let’s Connect at the BIO 2025 convention in Boston!

Author picture

We’re thrilled to share that our team will be attending the BIO 2025 International Convention, taking place from June 16–19, 2025, at the Boston Convention and Exhibition Center.

Representing our team:

Teresa Joseph, Business Development Manager, will be available to discuss our biometrics stand-alone services, offering robust data management, statistical analysis, and innovative solutions tailored to your clinical trial needs.

Fadi Achkar, Business Development Director, will be showcasing our deep therapeutic expertise and commitment to advancing rheumatology and dermatology research.

Whether you’re attending to explore new technologies, meet new collaborators, or stay ahead of industry trends, we’re all in.

SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.

Jeff Smith

Chef de la direction

Jeff Smith, Chef de la direction d’Indero Recherches, apporte près de 30 ans d’expérience dans l’industrie pharmaceutique et CRO, s’étant distingué par son leadership exceptionnel, sa vision stratégique et son innovation. L’expertise de Jeff couvre des opérations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matière de création de valeur, de gestion des partenaires et d’opérations CRO ont toujours contribué au succès dans ses fonctions précédentes. Sous la direction de Jeff, Indero continue d’étendre ses capacités, faisant progresser les connaissances médicales et les nouvelles thérapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

 Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≤3 days, and lowers costs, helping teams make informed go/no-go decisions faster.